Press Releases




No Image

Growing Awareness of CBD’s Multifaceted Nature Eases Pressure from Regulators

NEW YORK, Oct. 22, 2019 /PRNewswire/ — The growing awareness of cannabidiol or CBD‘s health benefits has pushed the market into mainstream retail. Researchers have praised CBD for its multi-faceted uses such as its ability to alleviate minor conditions like headaches. However, CBD can also be used to treat serious symptoms associated with medical conditions such as cancer, epilepsy, and multiple sclerosis. Moreover, researchers have mentioned that CBD helps with quitting smoking and also mitigates the withdrawal symptoms. As a result, several countries are considering decriminalizing cannabis and potentially looking into legalizing it for recreational and medicinal purposes. For instance, countries such as Portugal, Canada, Ireland, Jamaica, Australia, Germany, and South Africa have all legalized cannabis for medical applications. Meanwhile, countries such as New Zealand and Mexico are possibly exploring legalizing cannabis entirely. However, the process to legalize cannabis is a tedious and lengthy process. Subsequently, more countries are inclined to legalize just the CBD aspect of the plat. To note, CBD is a derivative of cannabis, but it does not imbue its user with psychoactive effects unlike its THC counterpart. However, after extensive clinical trials, researchers have highlighted that CBD does offer similar therapeutic effects. And now, many see legalizing CBD is yet another step to potentially fully legalizing cannabis. According to data compiled by Technavio, the global CBD market is expected to accelerate at a CAGR of 31% during the forecast period from 2018 to 2022. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), HEXO Corp. (NYSE: HEXO) (TSX: HEXO), MariMed Inc. (OTC: MRMD), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF)


No Image

Medical Marijuana, Inc. Subsidiary Kannaway® Joins U.S. Hemp Roundtable Board of Directors

SAN DIEGO, Oct. 22, 2019 /PRNewswire/ — Medical Marijuana, Inc. (“the Company”) (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has been selected as a member of the Board of Directors for the U.S. Hemp Roundtable.


No Image

Marijuana Company of America Begins Harvest at its CBD Hemp Farm

ESCONDIDO, Calif., Oct. 22, 2019 /PRNewswire/ — MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTCQB: MCOA), an innovative hemp and cannabis corporation, is pleased to announce the Company has begun its 2019 harvest at its CBD hemp farm in Scio, Oregon. With its joint venture partner, Global Hemp Group Inc. (CSE: GHG/ OTC: GBHPF/ FRANKFURT: GHG), MCOA has created joint venture subsidiary, Covered Bridge Acres Ltd. (CBA), which owns the hemp biomass that runs across 35 acres and incorporates environmentally friendly and biodegradable methods.



No Image

H+K Experts Available for Commentary and Analysis Post-Election

TORONTO, Oct. 21, 2019 /CNW/ – Hill+Knowlton Strategies’ public affairs experts are available for commentary and analysis on Election Day and the days that follow. The team is comprised of members from across the country, from all party lines and non-partisan viewpoints with a variety of in-depth expertise in national affairs, campaigns and digital media analysis.


No Image

Curaleaf Shareholders Agree to Extended Lock-up

WAKEFIELD, Mass., Oct. 21, 2019 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or “the Company”), a leading vertically integrated cannabis operator in the United States, today announced that its core shareholders representing approximately 75% of the issued and outstanding shares of the Company have entered into an amended and extended lock-up agreement. Since the Company’s reverse takeover transaction in October 2018, all shareholders holding individually more than 1% of the issued and outstanding shares have been subject to lock-up agreements.


No Image

Celebrity Endorsements Drive the CBD Industry to New Heights

NEW YORK, Oct. 21, 2019 /PRNewswire/ — Whereas cannabis used to be a taboo in most societies, now, the plant is becoming a topic that is publicly endorsed by millions. A handful of celebrities have even done their part to help bring the industry into the global spotlight with their support. Influential figures such as Seth Rogan, Snoop Dogg, Olivia Wilde, Jay Z, Danny DeVito, Wiz Khalifa, and Willie Nelson are just some of the outspoken celebrities helping to put cannabis on the map. Generally, most celebrities have either decided to create their own brand or invest in a cannabis-based operator. For instance, Willie Nelson operates his own cannabis company called “Willie’s Reserve.” On his site, he sells a variety of products such as pre-rolled joints, dried flower, edibles, and oil concentrates. However, after the passage of the U.S. Farm Bill, many decided to create a CBD brand. Notably, former New England Patriots tight end Rob Gronkowski partnered with Abacus Health to launch CBDMedic, a clinical retailer to help with pain management. Moreover, Gwyneth Paltrow’s lifestyle brand, Goop, announced that it will offer CBD beauty products on its online store, including CBD-based products such as tinctures, lotions, and edibles. Overall, the CBD marketplace is much more attractive because it is legal in the U.S. and many other countries for medicinal purposes. In the U.S., health officials ultimately legalized CBD because it does not cause psychotropic effects on the consumer, unlike its THC counterpart. However, regulators have noted that more research and clinical trials are still needed to further understand the efficacy of CBD, as well as its safety. Nonetheless, as research continues to ramp up, industry experts believe that CBD is the next upcoming and disruptive market. As a result, by 2024, the cannabis market is expected to reach USD 89.1 Billion from USD 14.5 Billion in 2018, according to Mordor Intelligence. Additionally, the market is expected to register a CAGR of 37% during the forecast period from 2019 to 2024. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Harvest Health & Recreation, Inc. (OTC: HRVSF) (CSE: HARV), KushCo Holdings, Inc. (OTC: KSHB), Emerald Health Therapeutics Inc. (OTC: EMHTF) (TSX-V: EMH)